Crossject Société Anonyme (ALCJ.PA)

3.15 €

-0.13 (-3.82%)
Rating:
Recommendation:
-
Symbol ALCJ.PA
Price 3.15 €
Beta 1.733
Volume Avg. 0.09M
Market Cap 81.923M
Shares () -
52 Week Range 1.408-3.94
1y Target Est -
DCF Unlevered ALCJ.PA DCF ->
DCF Levered ALCJ.PA LDCF ->
ROE 883.35% Strong Buy
ROA -25.13% Sell
Operating Margin -
Debt / Equity -675.17% Strong Sell
P/E -
P/B -11.61 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Patrick Alexandre
Healthcare
Medical Instruments & Supplies
Paris

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.